Welcome to our dedicated page for Ovation news (Ticker: OVATF), a resource for investors and traders seeking the latest updates and insights on Ovation stock.
Ovation Science Inc. (OVATF) is a pharmaceutical research leader developing patented transdermal technologies for cannabis-based therapeutics. This news hub provides investors and industry stakeholders with essential updates on the company's licensing partnerships, product innovations, and market expansion strategies.
Access official press releases detailing advancements in InvisiCare® technology, regulatory milestones, and financial developments. Our curated collection features updates on North American market entries, research collaborations, and intellectual property achievements that demonstrate Ovation's leadership in cannabinoid delivery systems.
Key content includes earnings reports, partnership announcements with cannabis producers, and clinical research progress. Track the company's expansion through strategic licensing agreements in regulated markets while maintaining focus on compliant operations and scientific validation.
Bookmark this page for streamlined access to Ovation Science's corporate communications. Check regularly for updates on technological breakthroughs and business developments that shape the future of topical cannabis applications in medical and wellness markets.
Ovation Science announces the launch of its patented transdermal cannabis products in Pennsylvania through licensee PA Options for Wellness. This marks Ovation's second US licensee, targeting a market with over 850,000 registered patients and caregivers across 170+ dispensaries. PA Options, operating six dispensaries under Vytal Options brand with 32,000 registered medical patients, will distribute Ovation's products under the 'Mood' brand.
The company's formulations utilize Invisicare® technology, showing 10 times greater CBD release through the skin compared to other tested products. Ovation is expanding its US presence, with ongoing operations in Nevada through Planet 13 and planned entry into Missouri via MidWest Roots in January 2025. The company has terminated its licensing agreement with Stash House Distribution for Oklahoma, New Mexico, and Mississippi.
Ovation Science Inc. announced the launch of its topical product line in Nevada with Planet 13 Holdings, Inc., featuring both cannabis and hemp-derived products. The partnership aims to expand brand presence and generate revenue for both companies. Ovation's proprietary skin delivery technology, Invisicare®, enhances product effectiveness, with significant CBD release compared to competitors. Planet 13's topicals include various ratios of CBD and THC for relaxation, relief, and recovery. The companies are optimistic about driving growth and optimizing gross margins through this collaboration.
Ovation Science Inc. has announced a new Supply and Distribution Agreement with Golfer's CBD Ltd. for its CBD topical products in the USA, UK, and Europe. This partnership aims to penetrate the lucrative golf market, which includes approximately 66.6 million golfers worldwide. By leveraging Golfer's CBD's established e-commerce and retail distribution channels, Ovation expects to generate immediate monthly revenues. Their patented skin delivery technology, Invisicare, allows for superior absorption of cannabinoids, giving Ovation a competitive edge. The initial launch in the USA is scheduled for April 2023.
Ovation Science Inc. (CSE: OVAT, OTCQB: OVATF) will exhibit at the MJ Unpacked conference from September 28-30, 2022, in Las Vegas. The company aims to meet potential licensees to promote its award-winning transdermal formulations and highlight licensing opportunities for its patented skin delivery technology, Invisicare®. With new patent protection until 2041 and expansion in states like Oklahoma and Missouri, Ovation anticipates significant interest in its products. CEO Terry Howlett emphasized the company's focus on effective cannabinoid delivery and the unique advantages of their formulations.
Ovation Science Inc. has been awarded a patent for its transdermal creams formulated with CBD and THC, valid until February 2041. This patent strengthens the company's market position by protecting its proprietary drug delivery system, Invisicare. It covers the composition and method for delivering CBD and THC through the skin. Ovation has also expanded its licensing to four additional U.S. states, increasing its market reach to over 2,800 dispensaries. The company’s innovative approach has resulted in products showing significantly better absorption rates compared to competitors.
Ovation Science Inc. has announced an exclusive licensing agreement with Stash House Distribution to expand its cannabis formulations into Oklahoma, Missouri, New Mexico, and Mississippi. This agreement aims to increase the company's market presence from 92 dispensaries in Nevada to over 2,800 dispensaries across five states. Ovation's products utilize the patented Invisicare® technology for enhanced cannabinoid delivery, promising a significant increase in revenue through royalties based on wholesale sales. The launch is expected to occur in Q4 of 2022.
